Skip to content
Screener

Edwards Lifesciences EW Q2 2026 earnings

Reported July 23, 2026 · After market close

Revenue$1.7BBeat by $40.8M
Adjusted EPS$0.78Beat by $0.04
Revenue estimate$1.7B
EPS estimate$0.74
“Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, which gives us confidence in our target of approximately 10% total company sales growth, on average, over the longer term. Our strategic focus coupled with our commitment to early innovation enables us to deliver meaningful impact for patients worldwide.”
Bernard Zovighian

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$1.7B
EPS estimate$0.74

Financials

Q2 2026

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$49.1B+9.1%
Enterprise value$47.36B—
P/E48.9×+16.0×
P/S7.5×-0.1×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp

Segments

By segment

See full
United States$1.0B+12.8%
Europe$439.6M+16.2%
Rest of World$201.5M+19.2%
Japan$96.4M+1.2%

By product

See full
Transcatheter Aortic Valve Replacement$1.3B+11.3%
Surgical$284.1M—
Transcatheter Mitral and Tricuspid Therapies$198.6M+47.7%

FAQ

When did Edwards Lifesciences report Q2 2026 earnings?
Edwards Lifesciences (EW) reported Q2 2026 earnings on July 23, 2026 after market close.
What were Edwards Lifesciences's Q2 2026 revenue and EPS?
Edwards Lifesciences reported revenue of $1.7B and adjusted eps of $0.78 for Q2 2026.
Did Edwards Lifesciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.7B by $40.8M. EPS beat the consensus estimate of $0.74 by $0.04.
How did Edwards Lifesciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.6% from $1.5B a year earlier.
Where can I find Edwards Lifesciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001099800-26-000038) and the 10-Q periodic report (0001099800-26-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.